Immunotherapy May Increase the Risk of Treatment Discontinuation in SCLC
Adding immunotherapy to chemotherapy may increase the risk of toxicity and likelihood of treatment discontinuation in patients with SCLC, a meta-analysis suggests.
Adding immunotherapy to chemotherapy may increase the risk of toxicity and likelihood of treatment discontinuation in patients with SCLC, a meta-analysis suggests.
An analysis of data from patients with cancer treated with immune checkpoint inhibitors sought to determine predictors of immune-related adverse effects in these patients.
In an oral presentation at the 2023 ONA Summit, a thoracic oncology nurse practitioner reviewed the advances in the treatment of NSCLC and management of related adverse effects.
A novel method of treating immune checkpoint inhibitor-associated myocarditis may decrease the risk of death from myotoxicity.
A prospective cohort study compared outcomes for patients with extensive-stage small cell lung cancer who were trial eligible and those were trial ineligible.
Sexual dysfunction may be common in cancer patients and survivors, but their sexual health is often overlooked.
Unstructured data obtained via natural language processing is superior to structured data for extracting quantitative information about patient smoking habits.
Patients with cancer experienced symptoms of PTSD during the first year of the COVID-19 pandemic, a French study suggests.
Critically ill patients with cancer who develop delirium have a higher risk of dying in the hospital or intensive care unit, a study suggests.
Cancer patients living in nursing homes are more likely to receive aggressive end-of-life care and die in the hospital, a study suggests.